PARIS, March 13 (Reuters) – Sanofi announced on Monday the acquisition of the American biotechnology company Provention Bio for 25 dollars per share, a cash transaction of 2.9 billion dollars.
With this acquisition, the French pharmaceutical group intends to acquire full ownership of an innovative treatment for type 1 diabetes, he said in a press release.
The treatment, TZIELD (teplizumab-mzwv), was approved in the United States last year and is the first and only drug indicated to delay the onset of clinical type 1 (or stage 3) diabetes in adults and children from the age of eight with stage 2 type 1 diabetes.
“The acquisition of Provention Bio fits perfectly with Sanofi’s mission to provide medicines that are either the first or the best in their pharmacotherapeutic class,” said Olivier Charmeil, executive vice president of the general practice division, quoted in the press release.
Sanofi will finance the acquisition by drawing on its cash. The transaction is expected to close in the second quarter of 2023.
(Written by Blandine Hénault, edited by Matthieu Protard)
What stocks to buy?
Making the best investments requires in-depth knowledge of the markets, their mechanisms, of the economy and involves diving into the heart of the strategy of each of the listed companies. The editorial staff of Investir does it for you and provides its subscribers with advice on more than 800 securities. Benefit from their buy, speculative buy, spread or sell recommendations by subscribing to Investir.
I discover the offers
